RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Answer about the linker"Not good for an investor with sufficient scientific background that wants to understand, as much as possible, every aspect of their drug candidate. That to me is a real communication problem and don't tell me it's too technical to really matter. The devil is often in the details."
It is getting comical, so please enlighten me how many of those 75% retail exciting shareholders have "scientific background" and base their investment thesis on the linker they chosed?
So the "communication problem" comes down to the choosing specific linker now. Let the scientists do what they are best at and if you want to worry about anything maybe underperforming SP would be a good start.